TY  - JOUR
A1  - Howe, Anita Y. M.
A1  - Rodrigo, Chaturaka
A1  - Cunningham, Evan Brian
A1  - Douglas, Mark
A1  - Dietz, Julia
A1  - Grebely, Jason
A1  - Popping, Stephanie
A1  - Sfalcin, Javier Alejandro
A1  - Parczewski, Milosz
A1  - Sarrazin, Christoph
A1  - Salazar, Adolfo de
A1  - Fuentes, Ana
A1  - Sayan, Murat
A1  - Quer, Josep
A1  - Kjellin, Midori
A1  - Kileng, Hege
A1  - Mor, Orna
A1  - Lennerstrand, Johan
A1  - Fourati, Slim
A1  - Di Maio, Velia Chiara
A1  - Chulanov, Vladimir
A1  - Pawlotsky, Jean-Michel
A1  - Harrigan, P. Richard
A1  - Ceccherini-Silberstein, Francesca
A1  - Garcia, Federico
T1  - Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
T2  - JHEP Reports
N2  - Although direct-acting antiviral medications effectively cure hepatitis C in most patients, sometimes treatment selects for resistant viruses, causing antiviral drugs to be either ineffective or only partially effective. Multidrug resistance is common in patients for whom DAA treatment fails. Older patients and patients with advanced liver diseases are more likely to select drug-resistant viruses. Collective efforts from international communities and governments are needed to develop an optimal approach to managing drug resistance and preventing the transmission of resistant viruses.
KW  - RAS
KW  - HCV
KW  - DAA
KW  - virologic failure
KW  - NS5A
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63111
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-631112
SN  - 2589-5559
N1  - Financial support
No financial support was received for the writing of this article. The initial SHARED development was funded in part by Merck and a User Partnership Program grant from Genome British Columbia to P.R.H and A.Y.M.H (UPP029). The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian (or any other) Government. C.R. and J.G. are supported by an NHMRC Investigator Grant (nos. 1173666, 1176131). An NHMRC Program Grant supported RAS testing and data collection by M.W.D. (1053206) and small grants from the Australian Centre for HIV and Hepatitis Virology Research, The University of Sydney, Western Sydney Local Health District Research Education Network, and the Robert W. Storr bequest to the Sydney Medical Foundation (University of Sydney). S.P. received personal fees from Gilead Sciences. Regarding the Italian data, the work was supported in part by the Italian Ministry of Instruction, University and Research (MIUR) (Bandiera InterOmics Protocollo PB05 1°), by the Italian Ministry of Health (RF-2016-02362422), and by Aviralia and Vironet C Foundations.
VL  - 4
IS  - 4, art. 100462
SP  - 1
EP  - 14
PB  - Elsevier B.V.
CY  - Amsterdam
ER  -